High Risk HPV Multiplex Assay Clinically Validated
By LabMedica International staff writers Posted on 04 Apr 2016 |
Persistent infection with at least one of the high-risk carcinogenic human papillomavirus (HPV) types is the primary risk factor for the development of cervical cancer and HPV is found in virtually all cases of cervical cancer and precursor lesions.
Providing clear information about infected HPV genotypes in the stage of infection, clearance, and persistence is important to manage patient monitoring and treatment; however, conventional cytology tests do not determine HPV infection, but detect only cytological abnormality.
Scientists at the Catholic University of Korea (Seoul, Republic of Korea) collected 1,137specimens from Korean women that were randomly selected from the liquid-based cervical specimens between January and June 2014. All specimens were collected with a cytobrush, and were placed in a Huro Path liquid-based cytology sampling device (CelltraZone; Seoul, Republic of Korea). They were stored at -70 °C until HPV testing. Each specimen was divided into two aliquots and then used for HPV detection tests. The cervical cytological examination was performed by experienced cytopathologists.
The investigators used the Anyplex II HPV HR detection kit (Seegene Inc.; Seoul, Republic of Korea) which is a new, multiplex, real-time polymerase chain reaction assay to detect individual 14 high-risk (HR) human papillomavirus (HPV) types in a single tube. For each sample, HPV detection and genotyping were performed using a CFX96 real-time thermocycler (Bio-Rad; Hercules, CA, USA). They compared the assay with the Hybrid Capture 2 (Qiagen; Valencia, CA) using the non-inferiority score test in a routine cervical cancer screening setting. The intra laboratory and inter laboratory agreements of HPV HR were also evaluated.
The scientists found that overall agreement between the two assays was 92.4% (1,051 of 1,137) with a κ value of 0.787. Clinical sensitivity of HPV HR for high-grade squamous intraepithelial lesions and cervical intraepithelial lesions grade 2 or worse was 94.4% and 92.5%, respectively. The respective values for Hybrid Capture 2 were 93.1% and 87.5%. Clinical sensitivity and specificity of HPV HR were not inferior to those of Hybrid Capture 2. The HPV HR showed good intra laboratory and inter laboratory reproducibility at 98.0% and 97.4% respectively.
The authors concluded that their data indicate that the HPV HR assay was highly comparable to HC2 for clinical equivalence and reproducibility based on international guidelines. The individual typing information for 14 hrHPV genotypes, including HPV-16 and HPV-18, provided by the HPV HR can be an important tool in patient management. The study was published in the March 2016 issue of the journal Archives of Pathology & Laboratory Medicine.
Related Links:
Catholic University of Korea
CelltraZone
Bio-Rad
Providing clear information about infected HPV genotypes in the stage of infection, clearance, and persistence is important to manage patient monitoring and treatment; however, conventional cytology tests do not determine HPV infection, but detect only cytological abnormality.
Scientists at the Catholic University of Korea (Seoul, Republic of Korea) collected 1,137specimens from Korean women that were randomly selected from the liquid-based cervical specimens between January and June 2014. All specimens were collected with a cytobrush, and were placed in a Huro Path liquid-based cytology sampling device (CelltraZone; Seoul, Republic of Korea). They were stored at -70 °C until HPV testing. Each specimen was divided into two aliquots and then used for HPV detection tests. The cervical cytological examination was performed by experienced cytopathologists.
The investigators used the Anyplex II HPV HR detection kit (Seegene Inc.; Seoul, Republic of Korea) which is a new, multiplex, real-time polymerase chain reaction assay to detect individual 14 high-risk (HR) human papillomavirus (HPV) types in a single tube. For each sample, HPV detection and genotyping were performed using a CFX96 real-time thermocycler (Bio-Rad; Hercules, CA, USA). They compared the assay with the Hybrid Capture 2 (Qiagen; Valencia, CA) using the non-inferiority score test in a routine cervical cancer screening setting. The intra laboratory and inter laboratory agreements of HPV HR were also evaluated.
The scientists found that overall agreement between the two assays was 92.4% (1,051 of 1,137) with a κ value of 0.787. Clinical sensitivity of HPV HR for high-grade squamous intraepithelial lesions and cervical intraepithelial lesions grade 2 or worse was 94.4% and 92.5%, respectively. The respective values for Hybrid Capture 2 were 93.1% and 87.5%. Clinical sensitivity and specificity of HPV HR were not inferior to those of Hybrid Capture 2. The HPV HR showed good intra laboratory and inter laboratory reproducibility at 98.0% and 97.4% respectively.
The authors concluded that their data indicate that the HPV HR assay was highly comparable to HC2 for clinical equivalence and reproducibility based on international guidelines. The individual typing information for 14 hrHPV genotypes, including HPV-16 and HPV-18, provided by the HPV HR can be an important tool in patient management. The study was published in the March 2016 issue of the journal Archives of Pathology & Laboratory Medicine.
Related Links:
Catholic University of Korea
CelltraZone
Bio-Rad
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Pathology News
- AI Integrated With Optical Imaging Technology Enables Rapid Intraoperative Diagnosis
- HPV Self-Collection Solution Improves Access to Cervical Cancer Testing
- Hyperspectral Dark-Field Microscopy Enables Rapid and Accurate Identification of Cancerous Tissues
- AI Advancements Enable Leap into 3D Pathology
- New Blood Test Device Modeled on Leeches to Help Diagnose Malaria
- Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing
- Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization
- First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests
- AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis
- New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance
- New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis
- Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse
- Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection
- Image-Based AI Shows Promise for Parasite Detection in Digitized Stool Samples
- Deep Learning Powered AI Algorithms Improve Skin Cancer Diagnostic Accuracy
- Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities